Products for Research Use Only

Tigulixostat

CAT: 0804-HY-139585-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-139585-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Tigulixostat (LC350189) is an orally active non-purine selective xanthine oxidase inhibitor. Tigulixostat has IC50 values of 0.003 µM and 0.073 µM in bovine milk and rat plasma, respectively. Tigulixostat can effectively reduce serum uric acid levels and can be used in the research of gout and hyperuricemia[1][2][3][4].
CAS Number
1287766-55-5
Product Name Alternative
LC350189
UNSPSC
12352005
Target
Xanthine Oxidase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/tigulixostat.html
Purity
99.18
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
N#CC1=CN(C(C)C)C2=C1C=C(N3N=CC(C(O)=O)=C3)C=C2
Molecular Formula
C16H14N4O2
Molecular Weight
294.31
References & Citations
[1]Seonghae Yoon, et al. Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects. Drug Des Devel Ther. 2015 Aug 31;9:5033-49. |[2]Terkeltaub R, et al. Serum Urate-Lowering Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Trial. Arthritis Rheumatol. 2023 Jul;75 (7) :1275-1284.|[3]Xue L, et al. Tigulixostat Alleviates Hyperuricemic Nephropathy by Promoting M2 Macrophage Polarization. J Inflamm Res. 2025 Jan 3;18:17-30.|[4]Kumar A, et al. AB0101 PRECLINICAL IN VITRO AND IN VIVO EFFICACY STUDIES OF TIGULIXOSTAT, A SELECTIVE NON-PURINE XANTHINE OXIDASE INHIBITOR. Annals of the Rheumatic Diseases, 2024, 83: 1284.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3

Alternative Products